Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Depression 3Breast Neoplasms 2Anxiety Disorders 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lung Neoplasms 1Hospice 1Hematopoietic and Lymphoid System Neoplasm 1Hematopoietic and Lymphatic System Neoplasm 1Hematologic Neoplasms 1Gynecologic Cancer 1Gastrointestinal Neoplasms 1Emotional Regulation 1Colonic Neoplasms 1Advanced Cancer 1Acute Pain 1

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × Psychotherapy × Clear all
NCT07336238 2026-05-29

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

University of Washington

Phase 2 Recruiting
18 enrolled

Anxiety Disorders, Depression, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡